Pembrolizumab Plus lenvatinib significantly improves survival in advanced endometrial cancer

0
331
Pembrolizumab Plus lenvatinib significantly improves survival in advanced endometrial cancer

The Gynecologic Oncology Institute reviews all recent advances for cancer treatment and this is a significant step forward, now part of the NCCN Guidelines for recurrent advanced endometrial cancer.

The combination of pembrolizumab (Keytruda) plus lenvatinib (Lenvima) resulted in statistically significant and clinically meaningful improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) compared to chemotherapy when treating patients with advanced endometrial cancer following prior systemic therapy in Phase 3 clinical KEYNOTE-775 / Study 309 (NCT03517449), according to a press release from Merck and Esai, developers of the regimen

The dual primary endpoints of OS and PFS and the secondary efficacy endpoint of ORR were met with the combination of anti-PD-1 therapy and lenvatinib, an orally available tyrosine kinase inhibitor with multiple receptors. The researchers observed these positive results in both the Mismatch Repair Proficient (pMMR) subgroup and the Intention-to-Treat (ITT) group. This included patients with endometrial cancer (pMMR) as well as patients with high microsatellite instability (MSI-H). / Mismatch repair defective (dMMR).

The combination also appeared to have a safety profile consistent with previous findings for the pembrolizumab plus lenvatinib regimen.

The most common toxicities of the regime were fatigue, high blood pressure, musculoskeletal pain, diarrhea, decreased appetite, hypothyroidism, nausea, stomatitis, vomiting, decreased weight, abdominal pain, headache, constipation, urinary tract infection, dysphonia, hemorrhagic events, hypomagnesemia, palmar-plant erythema, Difficulty breathing, cough, and rash.

References

1. The combination of Keytruda® (pembrolizumab) and Lenvima® (lenvatinib) showed a statistically significant improvement in overall survival, progression-free survival and objective response rate compared to chemotherapy in patients with advanced endometrial cancer after prior systemic therapy in the phase 3 study. Press release. Merck. December 16, 2020. Accessed December 16, 2020. https://yhoo.it/2WjJ8b6

2. Makker V., Rasco D., Vogelzang NJ, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multi-center, open-label, single-arm phase 2 study. Lancet Oncol. 2019; 20 (5): 711- 718. doi: 10.1016 / S1470-2045 (19) 30020-8.

Source link

Previous articleImpact of the COVID-19 Pandemic on Ovarian Cancer Management: Adapting to the New Normal
Next articleMany ovarian cysts do well without surgery
“I help and guide women to defeat gynecologic cancers and advanced pelvic conditions such as endometriosis, using a unique combination of minimally invasive robotic surgery, precision medicine therapies and complementary holistic natural support towards thriving in survivorship." Dr. Vasilev is the only physician quadruple board certified in Ob-Gyn, Gynecologic Oncology and Integrative & Holistic Medicine in the United States. He is an accomplished advanced robotic surgeon and serves as Medical Director of Integrative Medicine and Integrative Gynecologic Oncology at Providence Saint John's Health Center, Professor at John Wayne Cancer Institute in Santa Monica, California and is Clinical Professor at Loma Linda University School of Medicine. He is former faculty and professor at UC Irvine, UCLA, USC and City of Hope. He is an active member of multiple medical societies and has been nationally listed in "Best Doctors" for 18 years.